| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
BAXTER INTERNATIONAL INC. Reconciliation of Non-GAAP Financial Measures Projected Third Quarter and Full Year 2025 U.S. GAAP Sales Growth to Projected Operational Sales Growth and Projected Third Quarter and Full Year 2025 Adjusted Earnings Per Share (unaudited) | ||
| Sales Growth Guidance | Q3 2025* | FY 2025* |
| Sales growth - U.S. GAAP | 6% - 7% | 6% - 7% |
| Kidney Care MSA | (~300 bps) | (~300 bps) |
| Exit of IV Solutions in China | ~70 bps | ~50 bps |
| Foreign Exchange | (~100 bps) | (~50 bps) |
| Operational sales growth | 3% - 4% | 3% - 4% |
| Adjusted Earnings Per Share Guidance | Q3 2025 | FY 2025 |
| Adjusted diluted EPS | $0.58 - $0.62 | $2.42 - $2.52 |
| *Totals may not foot due to rounding |
Posted In: BAX
